Mohammad Hossein Jabbarpoor Bonyadi1, Mehdi Yaseri2, Mortaza Bonyadi3, Masoud Soheilian4. 1. Ocular Tissue Engineering Research Center, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Pasdaran Ave, Boustan 9th street, Tehran, Iran. mhbonyadi@yahoo.com. 2. Department of Biostatistics and Epidemiology, Tehran University of Medical Sciences, Tehran, Iran. 3. Center of Excellence for Biodiversity, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. 4. Ocular Tissue Engineering Research Center, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Pasdaran Ave, Boustan 9th street, Tehran, Iran.
Abstract
PURPOSE: To compare the published results of studies on the genotype association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V in cases diagnosed as retinal angiomatous proliferation (RAP) versus neovascular age-related macular degeneration (AMD) or healthy controls. METHODS: Heterogeneity of studies was evaluated using Cochran's Q test and I-square index. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA. RESULTS: Four studies were included with 1076 neovascular AMD patients, 222 RAP cases, and 2276 control subjects. Pooled overall odds ratios for RAP/AMD were 1.15 (95% CI 0.60-2.18) for GT versus GG, 3.52 (95% CI 1.25-9.91) for TT versus GG ARMS2, 0.98 (95% CI 0.22-4.29) for GA versus AA, 1.00 (95% CI 0.25-4.02) for GG versus AA CFHI62V, 0.57 (95% CI 0.35-0.93) for CT versus TT CFH Y402H, and 0.40 (95% CI 0.22-0.74) for CC versus TT CFH Y402H. Regression analysis showed that ARMS2 TT genotype has a statistically significant effect on RAP versus AMD compared to CFH genotypes (P < 0.001). CONCLUSION: This meta-analysis disclosed a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes.
PURPOSE: To compare the published results of studies on the genotype association of ARMS2/LOC387715 A69S, CFHY402H, and CFHI62V in cases diagnosed as retinal angiomatous proliferation (RAP) versus neovascular age-related macular degeneration (AMD) or healthy controls. METHODS: Heterogeneity of studies was evaluated using Cochran's Q test and I-square index. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA. RESULTS: Four studies were included with 1076 neovascular AMDpatients, 222 RAP cases, and 2276 control subjects. Pooled overall odds ratios for RAP/AMD were 1.15 (95% CI 0.60-2.18) for GT versus GG, 3.52 (95% CI 1.25-9.91) for TT versus GG ARMS2, 0.98 (95% CI 0.22-4.29) for GA versus AA, 1.00 (95% CI 0.25-4.02) for GG versus AA CFHI62V, 0.57 (95% CI 0.35-0.93) for CT versus TT CFHY402H, and 0.40 (95% CI 0.22-0.74) for CC versus TT CFHY402H. Regression analysis showed that ARMS2 TT genotype has a statistically significant effect on RAP versus AMD compared to CFH genotypes (P < 0.001). CONCLUSION: This meta-analysis disclosed a stronger effect of ARMS2 genotypes in RAP cases compared with CFHY402H and I62V genotypes.
Authors: Daniel E Weeks; Yvette P Conley; Hui-Ju Tsai; Tammy S Mah; Silke Schmidt; Eric A Postel; Anita Agarwal; Jonathan L Haines; Margaret A Pericak-Vance; Philip J Rosenfeld; T Otis Paul; Andrew W Eller; Lawrence S Morse; J P Dailey; Robert E Ferrell; Michael B Gorin Journal: Am J Hum Genet Date: 2004-05-27 Impact factor: 11.025
Authors: Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Elod Kortvely; Stefanie M Hauck; Gabriele Duetsch; Christian J Gloeckner; Elisabeth Kremmer; Claudia S Alge-Priglinger; Cornelia A Deeg; Marius Ueffing Journal: Invest Ophthalmol Vis Sci Date: 2009-08-20 Impact factor: 4.799
Authors: Gaofeng Wang; Kylee L Spencer; Brenda L Court; Lana M Olson; William K Scott; Jonathan L Haines; Margaret A Pericak-Vance Journal: Invest Ophthalmol Vis Sci Date: 2009-02-28 Impact factor: 4.799